AbbVie’s upadacitinib receives positive EU opinion for alopecia

AbbVie’s upadacitinib receives positive EU opinion for alopecia

Summary aggregated from Investing.com's public RSS feed. The full reporting belongs to Investing.com — please read it on their site.